The above findings potentially explain why IGH::MYC, but not non-IG::MYC confers significantly inferior survival in patients with DLBCL-MYC/BCL2-DH [7], and also why ~25% of DLBCL with MYC translocation, including those with a MYC/BCL2-DH, are conventional GCB, but not MHG subtype [1]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.